Physician profile
Keri D Smith
NPI 1245425867
$3,158.03
in general payments reported to CMS, 2019-2025
15 companies · $150 in 2025
The $150 reported for 2025 was more than what 75% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $245 · 2021: $558 · 2022: $916 · 2023: $500 · 2024: $350 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $793.96 | 2019-2024 | Andexxa |
| Janssen Pharmaceuticals, INC | $699.02 | 2019-2024 | Xarelto |
| Inari Medical, INC. | $320.68 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $245.55 | 2019-2022 | |
| Csl Behring | $218.82 | 2023-2025 | Kcentra |
| Btg International INC. | $187.08 | 2020-2025 | Crofab |
| Melinta Therapeutics, LLC | $167.92 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.08 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $97.91 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $75.67 | 2019 | |
| Pfizer INC. | $62.15 | 2019-2025 | |
| Chiesi USA, INC. | $60.74 | 2022 | |
| Abbvie INC. | $39.24 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $14.31 | 2025 | |
| Merck Sharp & Dohme LLC | $12.90 | 2023 | Dificid, Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.